Treatment of cancers using anti-NKG2A agents
AssigneeInnate Pharma
InventorsPascale Andre, Mathieu Blery, Caroline Soulas, Nicolai Wagtmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
Claims15
A method of treating a head and neck squamous cell carcinoma (HNSCC) in an individual, the method comprising administering to the individual an antibody that binds a human NKG2A polypeptide and neutralizes the inhibitory activity of NKG2A, wherein the NKG2A antibody comprises a heavy chain comprising SEQ ID NO:
- 2 and a light chain comprising SEQ ID NO:
- 7.
A method for treatment of a cancer in an individual, wherein the method comprises:
- a) determining the HLA-E polypeptide status of malignant cells from the individual having a cancer;
- b) determining the EGFR polypeptide status of malignant cells from the individual having a cancer;
- and
- c) upon a determination that HLA-E and EGFR polypeptides are expressed by malignant cells from the individual at levels that are at or above a reference level, administering to the individual a therapeutic regimen that comprises an antibody that neutralizes the inhibitory activity of a human NKG2A polypeptide and cetuximab, wherein the antibody comprises a heavy chain comprising SEQ ID NO:
- 2 and a light chain comprising SEQ ID NO:
- 7.
A method for treatment of a HNSCC in an individual, wherein the method comprises:
- a) determining whether the individual has a HNSCC characterized by the presence of lymphocytes in the tumor environment;
- and
- b) upon a determination that the individual has a HNSCC characterized by the presence of lymphocytes in the tumor environment, administering to the individual an antibody that neutralizes the inhibitory activity of a human NKG2A polypeptide, wherein the antibody comprises a heavy chain comprising SEQ ID NO:
- 2 and a light chain comprising SEQ ID NO:
- 7.
A method of treating a HNSCC in a human patient, the method comprising administering to the patient an effective amount of each of:
- (a) an antibody that neutralizes the inhibitory activity of human NKG2A, and (b) cetuximab, wherein the antibody that neutralizes the inhibitory activity of human NKG2A comprises a heavy chain comprising SEQ ID NO:
- 2 and a light chain comprising SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.